Isomorphic Labs raises $5bn
The Series C was co-led by Greenoaks and Sequoia Capital, with Alphabet and all existing investors taking part; Isomorphic reported preclinical results in oncology and immunology and gave no valuation.
- Money & business
- Ideas & essays
- Notable
Isomorphic Labs, the AI drug-design company founded in 2021 and, per TechCrunch, spun out of Google’s DeepMind, announced a $5 billion Series C. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and other new investors, “continued significant investment from Alphabet” and all existing investors, listed as Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. It follows a $600 million round in March 2025, the company’s first external funding; TechCrunch reported a $2.1 billion Series B in May 2026 in between.
Isomorphic said the money will scale its proprietary drug design engine, IsoDDE, which it describes as a suite of foundational simulation models spanning therapeutic areas and drug modalities, along with its candidate pipeline and the clinical-development infrastructure needed to take candidates into trials. The company reported “positive preclinical results, both for internal programs in oncology and immunology and with partners, setting the stage for clinical entry.” It did not name a candidate, a target or a trial date, and the release gives no data behind the preclinical claim.
Demis Hassabis, who is the company’s founder and chief executive and who stepped down as Google DeepMind’s chief executive in August, said the round would help drive “our first therapeutic programs towards clinical trials”. President Max Jaderberg said the team makes “repeatable scientific advancements” every week. Both statements are company claims. Isomorphic did not disclose a valuation, and TechCrunch noted that none was given.
The sources reviewed report no drug from the company in human trials; the company says the round is meant to move its first programmes there.
In the commentary
What people were saying around this time — external links, from the record's commentary rail.